On Monday, September 17th make sure to tune into the daily morning show The Balancing Act at on the Lifetime network. Cohosts Olga Villaverde and Amber Milt will meet MPN experts Dr. Richard T. Silver, from NewYork–Presbyterian/Weill Cornell Medical Center, and Dr. Srdan Verstovsek of the MD Anderson Cancer Center, to discuss the latest in patient care and clinical… Read More »BEHIND THE MYSTERY: LIVING WITH POLYCYTHEMIA VERA
In an article published by CURE Today, MPN Research Foundation’s Executive Director, Michelle Woehrle, sat down with Senior Editor, Katie Kosko, to discuss the effort to improve stem cell transplant outcomes for MF patients with the launch of the SCT Spectrum Transplant Timing tool (SSTT). The tool, sponsored by MPNRF, was launched in July with the help of a taskforce made… Read More »MPN RESEARCH FOUNDATION’S SCT SPECTRUM TRANSPLANT TIMING TOOL FEATURED IN CURE TODAY
A recent analysis of the Swedish Cancer Family Database, which includes 95,000 first degree relatives of 35,000 cancer patients and has been collected since 1958 has found there is a familial predisposition for certain blood cancers, including myeloproliferative neoplasms. The article states “The research shows that risk of myeloid cancers is passed on through families,”… Read More »RECENT STUDY INDICATES A FAMILIAL PREDISPOSITION FOR MPN
In an article published by CURE Magazine MPN Research Foundation’s registry manager, Lindsey Whyte, sat down with Brielle Urciuoli to discuss the benefits that myMPN brings to the MPN research community. The main objective of MPNRF’s patient registry is to expedite the development of targeted disease therapies by providing the research community with firsthand information… Read More »MPN RESEARCH FOUNDATION’S PATIENT REGISTRY FEATURED IN CURE TODAY
Patients with a pre-existing B-cell clone in their bone marrow are more likely to develop lymphoma after taking a JAK2 inhibitor, a study from Austria has found. Heinz Gisslinger, MD, found that patients with this alteration in the B cell lineage, who had taken a JAK2 inhibitor, were 16 times more likely to develop B Cell… Read More »SCREENING FOR B CELL CLONE PRIOR TO TAKING A JAK2 INHIBITOR SUGGESTED
What started as a series of questions about how long it would take to realize an immunotherapy based treatment for Polycythemia Vera, Essential Thrombocythemia and Myelofibrosis resulted in a meeting of the minds in Chicago’s Gleacher Center. The MPNRF has funded several immunotherapy related projects focused on the MPNs, but the questions remained of what… Read More »MPNRF HOSTS MEETING OF THE MINDS ON THE FUTURE OF IMMUNOTHERAPY IN MPN
HikeMF, an annual fundraising event organized by Julie Rittenburg Libon and Lori Rittenburg Small, took place at Borderland State Park in North Easton, MA this past Saturday, June 2nd. Over 130 people came out to participate in the 3-milehike, and this year all proceeds benefit the MPN Research Foundation’s Challenge Grants program. The event raised… Read More »HIKEMF 2018 RAISES $35,000 FOR MPN RESEARCH FOUNDATION!
Watch the video below from news outlet ABC 7 Chicago and learn about how Interferon changed the life of ET patient, Karrie Schwartz. Interferon is an off-label drug that is currently the only treatment to provide disease-altering effects for MPN patients. However, we don’t understand why it works and why it works for some patients… Read More »INTERFERON CHANGES LIFE OF ESSENTIAL THROMBOCYTHEMIA PATIENT, KARRIE SCHWARTZ
Dr. Ruben Mesa, longtime friend and collaborator of MPN Research Foundation, sat down with Krista Rossi from Rare Disease Report at ASCO 2018 to discuss his views on the current climate of myeloproliferative neoplasms and other rare cancers. Dr. Mesa provided updates on emerging innovations, discussed the greatest obstacles facing the treatment of rare diseases and his support for… Read More »DR. RUBEN MESA FEATURED IN RARE DISEASES REPORT MAGAZINE
